Clinton Musil
Algemeen Directeur bij Skyhawk Therapeutics, Inc.
Profiel
Clinton Musil is currently the Chief Executive Officer at Skyhawk Therapeutics, Inc. He previously held positions as Vice President in the Healthcare Investment Banking Group at Wells Fargo & Co. and Deutsche Bank AG.
He also served as the Chief Business Officer at Personalis, Inc., Principal at Needham & Co. LLC, and Vice President at Essex Woodlands Management, Inc. Additionally, he was the Vice President of Corporate Development at ARMO BioSciences, Inc. from 2017 to 2018.
In 2020, he became the Chief Financial Officer at Catalyst Biosciences, Inc. before transitioning to the role of Chief Financial Officer at Skyhawk Therapeutics, Inc. in 2021.
Mr. Musil obtained his undergraduate degree from the University of Arizona and holds an MBA from Harvard Business School.
Actieve functies van Clinton Musil
| Bedrijven | Functie | Begin |
|---|---|---|
Skyhawk Therapeutics, Inc.
 Skyhawk Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Skyhawk Therapeutics, Inc. discovers and develops small molecule therapeutics for RNA-based disease. It is developing drug candidates for cancer, neurological disease, and rare disease. The company was founded by William M. Hanley III and Kathleen McCarthy and is headquartered in Waltham, MA. | Algemeen Directeur | 11-06-2024 |
Eerdere bekende functies van Clinton Musil
| Bedrijven | Functie | Einde |
|---|---|---|
Skyhawk Therapeutics, Inc.
Skyhawk Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Skyhawk Therapeutics, Inc. discovers and develops small molecule therapeutics for RNA-based disease. It is developing drug candidates for cancer, neurological disease, and rare disease. The company was founded by William M. Hanley III and Kathleen McCarthy and is headquartered in Waltham, MA. | Financieel Directeur/CFO | 01-02-2024 |
| CATALYST BIOSCIENCES | Financieel Directeur/CFO | 29-10-2021 |
| ARMO BIOSCIENCES INC | Corporate Officer/Principal | 01-07-2018 |
| DEUTSCHE BANK AG | Corporate Officer/Principal | 01-03-2017 |
| WELLS FARGO & COMPANY | Corporate Officer/Principal | 01-07-2014 |
Opleiding van Clinton Musil
| University of Arizona | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| PERSONALIS, INC. | Health Services |
| DEUTSCHE BANK AG | Finance |
| WELLS FARGO & COMPANY | Finance |
| Bedrijven in privébezit | 5 |
|---|---|
Essex Woodlands Management, Inc.
 Essex Woodlands Management, Inc. Investment ManagersFinance Essex Woodlands Management, Inc. (EW Healthcare Partners) is a private equity firm founded in 1985 by Jim L. Currie and Martin P. Sutter. The firm is headquartered in Houston, Texas. | Finance |
Needham & Co. LLC
 Needham & Co. LLC Investment Banks/BrokersFinance Needham & Co. LLC (Needham) is a registered investment advisor and broker/dealer headquartered in New York City. The firm was founded in 1985 and is a wholly-owned indirect subsidiary of The Needham Group, Inc. Needham provides corporate and institutional clients with high quality research, corporate access, capital markets and trading execution services in both the public and private markets, with an emphasis on growth companies. | Finance |
ARMO BioSciences, Inc.
 ARMO BioSciences, Inc. Pharmaceuticals: MajorHealth Technology ARMO BioSciences, Inc. develops immunotherapy for the treatment of cancer, cardiovascular diseases, fibrosis, and inflammation. Its lead product candidate is AM0010 (pegilodecaki). The company was founded by Peter Van Vlasselaer, Martin Oft, and John B. Mumm on June 23, 2010 and is headquartered in Redwood, CA. | Health Technology |
Catalyst Biosciences, Inc.
 Catalyst Biosciences, Inc. BiotechnologyHealth Technology Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA. | Health Technology |
Skyhawk Therapeutics, Inc.
Skyhawk Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Skyhawk Therapeutics, Inc. discovers and develops small molecule therapeutics for RNA-based disease. It is developing drug candidates for cancer, neurological disease, and rare disease. The company was founded by William M. Hanley III and Kathleen McCarthy and is headquartered in Waltham, MA. | Health Technology |
